Skip to main content
Top
Published in: Breast Cancer Research 2/2006

01-11-2006 | Poster Presentation

Setting a lower risk threshold for surveillance within breast cancer family services

Authors: R Black, A Fordyce, M Reis, D Goudie, L McLeish, H Carnaghan, E Anderson, J Campbell, H Gregor, E Smyth, R Davidson, M Steel

Published in: Breast Cancer Research | Special Issue 2/2006

Login to get access

Excerpt

Counselling, risk assessment and surveillance are provided for women with a significant family history of breast cancer through a network of clinical centres across the United Kingdom. Before 2004, the recommended minimum 'threshold' for significant familial risk was set by a number of guidelines issued, which broadly required one first-degree relative diagnosed with breast cancer before age 40 or two close relatives both diagnosed before age 60. In 2004, NICE issued detailed guidelines in which the age requirement for two affected relatives was removed. However, it is widely recognised that the evidence base for any specific minimum threshold is limited and that there is a need for empirical studies to validate current and future recommendations. That is the object of the present study. …
Metadata
Title
Setting a lower risk threshold for surveillance within breast cancer family services
Authors
R Black
A Fordyce
M Reis
D Goudie
L McLeish
H Carnaghan
E Anderson
J Campbell
H Gregor
E Smyth
R Davidson
M Steel
Publication date
01-11-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1597

Other articles of this Special Issue 2/2006

Breast Cancer Research 2/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine